Mr. James Yamanaka reports

ORGANIGRAM PROVIDES BUSINESS UPDATE HIGHLIGHTING INITIAL SANITY PERFORMANCE AND CANADIAN MARKET SHARE

Following its acquisition of Sanity Group GmbH, Organigram Global Inc. has provided a business update highlighting initial operating performance from Sanity, continued strength in its Canadian business and coming investor engagement.

"The first quarter following the acquisition of Sanity marks an important milestone for Organigram as we will begin reporting the financial contribution from our international business," said James Yamanaka, chief executive officer. "Sanity's initial performance has been consistent with our expectations at the time of acquisition, while our Canadian business continues to demonstrate resilience through market leadership, improving category trends and disciplined execution. We look forward to providing investors with our first full quarter of consolidated financial results in August and discussing our longer-term strategy during our investor session in September."

Sanity Group performance

The company is providing investors with an initial update on Sanity's operating performance following the completion of the acquisition in April, 2026.

Since the closing of the acquisition on April 15, 2026, Sanity has maintained an average market share of approximately 10 per cent in Germany and has performed in line with the revenue expectations established at the time of acquisition, supporting management's confidence in the long-term opportunity within Germany's growing medical cannabis market.

The company also notes that recently announced regulatory changes in Germany regarding reimbursement eligibility for medical cannabis are not expected to have a material impact on Sanity's business as reimbursement-based sales represent approximately 1 per cent of Sanity's total revenue.

Canadian market share

Organigram continues to maintain leading positions across Canada's largest cannabis categories, including:

• No. 1 in flower -- 12.5-per-cent share of the flower category;
• No. 1 in vapes -- 14.5-per-cent share of the vape category;
• No. 2 in prerolls -- 7.3-per-cent share of the preroll category.

Together, these categories represent more than 86 per cent of total Canadian recreational cannabis retail sales.

The company also recorded significant year-over-year market share gains in beverages (plus 3.1 percentage points) and concentrates (plus 3.3 percentage points).

During June, Organigram stabilized the vape market share declines experienced earlier in Q2 fiscal 2026, with all-in-one-vape share improving approximately one percentage point compared with the previous month. Distribution of the company's new all-in-one-vape portfolio has now expanded to every Canadian province except Nova Scotia and Quebec.

Similarly, both preroll and infused preroll market share improved sequentially during June, reflecting operational improvements implemented during Q2 fiscal 2026.

At the end of June, Organigram held 11.1-per-cent Canadian recreational cannabis market share, down 0.4 percentage point year over year. Sequentially, the company's market share improved 100 basis points versus May. Sequential market share improvements in June across vape and preroll categories provide positive early indicators that the commercial and operational initiatives put in place in Q2 fiscal 2026 are beginning to positively impact performance.

The company continues optimizing its SKU (stock-keeping unit) count to focus its resources on delivering higher SKU-level performance and delivering operational efficiencies across the board.

Q3 fiscal 2026 reporting and digital investor session

Organigram expects to report its Q3 fiscal 2026 financial results on or about Aug. 11, 2026, representing the first quarter to include consolidated financial results from both Organigram and Sanity.

Additional details regarding the quarterly earnings conference call will be announced in the coming weeks.

The company also intends to host its second digital investor session in late September, 2026.

The session will provide investors with Organigram's most comprehensive strategic update since the Sanity acquisition and is expected to include:

• Presentations from executive leadership;
• Operational updates from employees across Organigram's production facilities;
• Discussions regarding Canadian and international growth initiatives;
• Capital allocation and strategic priorities;
• A fireside question-and-answer session with management.

Additional details, including registration information and instructions for submitting questions, will be provided in advance of the event.

About Organigram Global Inc.

Organigram Global is a company (listed on the Nasdaq Global Select Market and Toronto Stock Exchange) whose wholly owned subsidiaries include Organigram Inc., a licensed cultivator and processor. Through its acquisition of Sanity Group, Organigram participates in the German medical cannabis market and other emerging markets within Europe.

Organigram is focused on producing high-quality cannabis for adult consumers as well as extending the company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, Shred, Monjour, Tremblant, Collective Project, Trailblazer, Boxhot and Debunk. Through its acquisition of Sanity Group, Organigram's European brands include Vayamed, avaay, Zoiks, Endosane, Vaay and Grashaus. Organigram operates facilities in Moncton, N.B., and Lac Superieur, Que., with a dedicated edibles manufacturing facility in Winnipeg, Man. The company also operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities and is optimized for formulation refinement, postprocessing of minor cannabinoids and infused preroll production. The facility in London will be optimized for labelling, packaging and national fulfilment. The company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.

We seek Safe Harbor.